Tamoxifen induces fatty liver disease in breast cancer through the MAPK8/FoxO pathway

Abstract excerpt

BACKGROUND: Prevention of metabolic complications of long-term adjuvant endocrine therapy in breast cancers remained a challenge. We aimed to investigate the molecular mechanism in the development of tamoxifen (TAM)-induced fatty liver in both estrogen receptor (ER)-positive and ER-negative breast cancer. METHODS AND RESULTS: First, the direct protein targets (DPTs) of TAM were identified using DrugBank5.1.7. We...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Risks and Factors
• Share to FOXO transcription factor regulation
• Share to Metabolism, Diabetes, and Cancer